<DOC>
	<DOCNO>NCT01634724</DOCNO>
	<brief_summary>To test whether GnRHa withhold 2-3 day ovulation trigger reduces incidence ovarian hyperstimulation syndrome ( OHSS ) infertile high-risk patient polycystic ovary ( PCOs ) treat gonadotropin vitro fertilization ( IVF ) Intracytoplasmic sperm injection ( ICSI ) .</brief_summary>
	<brief_title>GnRH Agonist ( GnRHa ) Withdrawal Late Stage Long Protocol Incidence Ovarian Hyper-stimulation</brief_title>
	<detailed_description>All patient receive midluteal long GnRH agonist ( GnRH-a ) gonadotropin ( recombinant FSH ) stimulation protocol . Pituitary down-regulation GnRH agonist ( triptorelin , 0.1mg/d , ×10d , 0.05mg/d E2 ≤40 pg/ml serum ) , initiate luteal phase cycle-day 21 . Two week later , E2 serum ≤40 pg/ml absence follicular activity detect , stimulation ovary start recombinant follicle-stimulating hormone ( recFSH , Gonal-F , Serono , Switzerland ) dose range 150-250 IU/d . Doses adjust accordingly ovarian monitoring follicle growth . GnRHa ( 0.05mg/d ) inject stimulously FSH dominant follicle ≥ 14 mm . When diameter one follicles ≥ 14 mm , GnRHa ( 0.05mg/d ) withheld study group . In control group , GnRHa use day ovulation trigger . Ovulation induce HCG ( 5000-10000 IU ) least three follicle great 16mm diameter detect ultrasound examination lead follicle reach ≥ 18 mm diameter . Oocytes retrieval IVF ICSI perform 34-36 hour later transvaginal ultrasound guidance . Main Outcome Measure ( ) : Serum E2 level , VEGF level Serum follicular fluid , retrieve oocyte , fertilization , implantation rate pregnancy rate ( PR ) , rate OHSS .</detailed_description>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>ninetysix infertile patient PCOs ( 12 follicle 29 mm diameter detect ovary ultrasound detection ) undergo IVF treatment enrol . subject include following : basal FSH level &gt; 10IU/L ; age &gt; 35 year ; body mass index ( BMI ) &gt; 30 kg/m2 ; ovarian surgery radiotherapy chemotherapy ; ovarian dysfunction ; endometriosis ; hyperprolactinemia ; thyroid dysfunction ; presence organic pelvic disease .</criteria>
	<gender>Female</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>GnRH agonist withdrawal</keyword>
	<keyword>OHSS</keyword>
	<keyword>E2</keyword>
	<keyword>VEGF</keyword>
</DOC>